Venetoclax is a novel cancer therapy being developed by Roche and AbbVie. The U.S. FDA has accepted the New Drug Application and granted Priority Review and Breakthrough Therapy Designation for venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Continue reading
This example of personalized medicine involves exploiting the highly selective proteins that are expressed by patients’ B-cells. Bullet Biotechnology isolates the specific idiotypic (Id) protein from patients with B-cell lymphomas (CLL – chronic lymphocytic leukemia, and NHL – non-Hodgkin’s lymphoma) and expresses it on the surface of a virus-like particle to provoke a highly specific anti-Id response against B-cell clones expressing the specific Id protein. Continue reading